Shares of UniQure surged on Wednesday following the company's announcement that the FDA granted approval for it to resubmit its gene therapy for Huntington's disease. The stock skyrocketed by nearly 80% in response to this news. This development has garnered significant attention in the investor community, as UniQure's innovative gene therapy has the potential to have a profound impact on treating this debilitating disease.